Scientists at Iceland-based human genome specialist deCODE genetics and academic colleagues from the Netherlands and 12 other countries across Europe and North America yesterday reported the discovery of a common single-letter variation (SNP) in the sequence of the human genome conferring risk of a range of vascular diseases.
The SNP confers risk of abdominal aortic aneurysm (AAA), early-onset heart attack, peripheral artery disease (PAD) and pulmonary embolism, independent of other known risk factors. It will be integrated into deCODE's DNA-based tests to improve the assessment of individual risk and the targeting of screening and prevention strategies. The SNP, rs7025486, is located in an intron of the DAB21P gene on chromosome 9q33. The gene encodes an inhibitor of cell growth and survival that is expressed in cardiovascular tissue.
Empowering physicians to identify at-risk patients
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze